NASDAQ:GTHX G1 Therapeutics (GTHX) Stock Price, News & Analysis → The Long-Awaited End of America Update (From Stansberry Research) (Ad) Free GTHX Stock Alerts $4.44 +0.31 (+7.51%) (As of 05:43 PM ET) Add Compare Share Share Today's Range$4.13▼$4.5150-Day Range$2.15▼$4.8852-Week Range$1.08▼$5.00Volume730,953 shsAverage Volume1.26 million shsMarket Capitalization$232.26 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get G1 Therapeutics alerts: Email Address G1 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside96.5% Upside$8.67 Price TargetShort InterestHealthy4.63% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.56Based on 19 Articles This WeekInsider TradingSelling Shares$151,904 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.64) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.14 out of 5 starsMedical Sector146th out of 924 stocksPharmaceutical Preparations Industry50th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.63% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in G1 Therapeutics has recently decreased by 12.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 2.5 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for G1 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,904.00 in company stock.Percentage Held by InsidersOnly 8.23% of the stock of G1 Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 24.21% of the stock of G1 Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($0.64) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 6.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About G1 Therapeutics Stock (NASDAQ:GTHX)G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More GTHX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHX Stock News HeadlinesMay 2, 2024 | markets.businessinsider.comOptimistic Buy Rating for G1 Therapeutics Amidst Solid Financial Footing and Cosela’s Market ExpansionMay 2, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...May 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.May 1, 2024 | finance.yahoo.comQ1 2024 G1 Therapeutics Inc Earnings CallMay 1, 2024 | markets.businessinsider.comEvaluating G1 Therapeutics: Insights From 5 Financial AnalystsMay 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | msn.comGTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024May 1, 2024 | msn.comG1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlookMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.May 1, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment with Analyst Revenue ProjectionsMay 1, 2024 | globenewswire.comG1 Therapeutics Provides First Quarter 2024 Financial Results and Operational HighlightsMay 1, 2024 | globenewswire.comG1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for LerociclibApril 30, 2024 | markets.businessinsider.comHere's what Wall Street expects from G1 Therapeutics's earningsApril 30, 2024 | msn.comG1 Therapeutics Q1 2024 Earnings PreviewApril 29, 2024 | americanbankingnews.comG1 Therapeutics (GTHX) Scheduled to Post Quarterly Earnings on WednesdayApril 19, 2024 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To ProfitApril 17, 2024 | finance.yahoo.comG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024April 17, 2024 | globenewswire.comG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024April 12, 2024 | markets.businessinsider.comBuy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment AppealApril 12, 2024 | markets.businessinsider.comBreaking Down G1 Therapeutics: 5 Analysts Share Their ViewsApril 4, 2024 | globenewswire.comG1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 22, 2024 | marketwatch.comG1 Therapeutics Cuts Executive Salaries by 10% Amid Cost-Cutting MeasuresMarch 22, 2024 | seekingalpha.comWhy G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech LandscapeMarch 16, 2024 | finance.yahoo.comGTHX Apr 2024 3.000 callMarch 16, 2024 | finance.yahoo.comGTHX Apr 2024 3.500 putMarch 6, 2024 | finance.yahoo.comGTHX Mar 2024 3.000 putSee More Headlines Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+126.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,970,000.00 Net Margins-58.13% Pretax Margin-54.36% Return on Equity-106.04% Return on Assets-33.99% Debt Debt-to-Equity Ratio1.46 Current Ratio3.87 Quick Ratio3.45 Sales & Book Value Annual Sales$82.51 million Price / Sales2.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book6.07Miscellaneous Outstanding Shares52,310,000Free Float48,000,000Market Cap$216.04 million OptionableOptionable Beta1.71 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. John E. Bailey Jr. (Age 59)CEO, President & Director Comp: $1.06MMr. Mark Avagliano (Age 48)Chief Business Officer Comp: $628.54kMr. John W. Umstead V (Age 39)Chief Financial Officer Mr. Terry L. Murdock (Age 64)Chief Operating Officer Comp: $541.59kMr. William C. Roberts (Age 55)Vice President of Investor Relations & Corporate Communications Ms. Monica R. ThomasGeneral Counsel & Chief Compliance OfficerMr. Evan Hicks M.B.A.Vice President of MarketingDr. Rajesh K. Malik Ch.B. (Age 65)M.B., M.D., Chief Medical Officer Comp: $596.37kMr. Andrew Perry (Age 51)Chief Commercial Officer Comp: $568.6kMr. Jeff MacdonaldSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsVeruNASDAQ:VERUEliem TherapeuticsNASDAQ:ELYMTelomir PharmaceuticalsNASDAQ:TELODesign TherapeuticsNASDAQ:DSGNZevra TherapeuticsNASDAQ:ZVRAView All CompetitorsInsiders & InstitutionsDenali Advisors LLCSold 35,700 shares on 4/19/2024Ownership: 0.165%John W V UmsteadSold 6,547 sharesTotal: $19,771.94 ($3.02/share)Birchview Capital LPSold 40,000 shares on 2/15/2024Ownership: 0.154%FinTrust Capital Advisors LLCBought 100,715 shares on 2/13/2024Ownership: 0.194%Rajesh MalikSold 28,600 sharesTotal: $132,132.00 ($4.62/share)View All Insider TransactionsView All Institutional Transactions GTHX Stock Analysis - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price target for 2024? 4 Wall Street research analysts have issued twelve-month target prices for G1 Therapeutics' stock. Their GTHX share price targets range from $5.00 to $12.00. On average, they predict the company's stock price to reach $8.67 in the next year. This suggests a possible upside of 96.5% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2024? G1 Therapeutics' stock was trading at $3.05 on January 1st, 2024. Since then, GTHX stock has increased by 44.6% and is now trading at $4.41. View the best growth stocks for 2024 here. Are investors shorting G1 Therapeutics? G1 Therapeutics saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 2,420,000 shares, a decrease of 12.3% from the March 31st total of 2,760,000 shares. Based on an average daily trading volume, of 1,290,000 shares, the short-interest ratio is currently 1.9 days. View G1 Therapeutics' Short Interest. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) posted its quarterly earnings data on Wednesday, May, 1st. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The business had revenue of $14.48 million for the quarter, compared to analyst estimates of $15.21 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 106.04% and a negative net margin of 58.13%. During the same period in the prior year, the company posted ($0.53) EPS. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? G1 Therapeutics (GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Denali Advisors LLC (0.16%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, John W V Umstead, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GTHX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressYour bank is lying to you.MyBankTrackerForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.